Genome-wide identification of m6A-associated single-nucleotide polymorphisms in Parkinson's disease. (15th October 2020)

• Record Type: Journal Article
• Authors: Qiu, Xiaohui; He, Honghu; Huang, Yanning; Wang, Jin; Xiao, Yousheng
• Is Part Of: Neuroscience letters. Volume 737(2020)
• Publication Date: 2020-10-15
• Subjects: Parkinson's disease -- Genome-wide association study -- Single nucleotide polymorphisms -- m6A; Neurology -- Periodicals; Neurology -- Periodicals; Research -- Periodicals; Neurologie -- Périodiques; Neuroanatomie -- Périodiques; Neuropharmacologie -- Périodiques; Neurophysiologie -- Périodiques; Neurology; Periodicals; Electronic journals; 617.48
• DOI: 10.1016/j.neulet.2020.135315
• Languages: English
• ISSNs: 0304-3940

Abstract

Highlights: The potential role of m 6 A-SNPs in PD were investigated using large-scale genome-wide association studies datasets. Twelve m 6 A-SNPs were retrieved from genome-wide association studies. Five m 6 A-SNPs were associated with a risk of PD. Abstract: N 6 -methyladenosine (m 6 A)-associated single nucleotide polymorphisms (SNPs) play a vital role in several neurological diseases. However, little is known about the relationship between m 6 A modification and Parkinson's disease (PD). We investigated potential functional variants of m 6 A-SNPs from large-scale genome-wide association studies (GWAS) in PD patients. The candidate m 6 A-SNPs were further assessed by expression quantitative trait loci (eQTL) analysis and differential gene expression analysis. We identified 12 m 6 A-SNPs that were significantly associated with PD risk. Further, eQTL and expression analyses identified five of these m 6 A-SNPs (rs75072999 of GAK, rs1378602, rs4924839 and rs8071834 of ALKBH 5, and rs1033500 of C6orf10 ) that were associated with altered gene expression in PD. Our results suggest that m 6 A-SNPs could play a role in PD risk. Future studies are needed to confirm these PD-associated m 6 A-SNPs and elucidate their mechanisms.